Anifrolumab in Refractory Juvenile Dermatomyositis

Area of Science:

• Immunology
• Pediatric Rheumatology
• Dermatology

Background:

• Juvenile dermatomyositis (JDM) is a rare autoimmune disease affecting children, characterized by muscle and skin inflammation.
• Current treatments, including corticosteroids and immunosuppressants, often fail to achieve sustained remission in refractory cases.

Observation:

• A case report details an 8-year-old girl with refractory JDM who did not respond to multiple therapies.
• The patient received anifrolumab, a monoclonal antibody targeting the type I interferon receptor.

Findings:

• Following anifrolumab treatment, the patient exhibited marked improvement in both skin and muscle symptoms.
• Disease activity scores significantly decreased, with sustained response over six months and no adverse effects.
• This is the third reported case demonstrating anifrolumab's efficacy in JDM.

Implications:

• Targeting the type I interferon (IFN-I) pathway represents a potential therapeutic strategy for refractory JDM.
• IFN-I dysregulation is implicated in dermatomyositis pathogenesis.
• Anifrolumab offers a promising option for difficult-to-treat pediatric inflammatory myopathies.